Research News 2

virus-concept-purple-research

Research News

1 | 2 | 3

  • Keeping Dormant HIV Dormant

    Researchers aim to find out if safe and effective drugs can be developed to permanently suppress the HIV reservoir.


  • Why Do Some Elite Controllers Stop Controlling HIV?

    A small minority of people living with HIV can suppress their viral load to levels at which the risk of HIV transmission and disease development are very low—all in the absence of antiretroviral therapy.


  • Another HIV Vaccine Failure – What HIV and COVID Can Teach Each Other

    At the end of the roughly four-year study, there were no significant differences in HIV acquisition between those who received the vaccine and those who got placebo.  


  • A Promising, “Unusual” Approach to Targeting HIV Spike Protein

    es of monoclonal antibodies were generated from rabbits immunized with a chemically stabilized form of the gp120/gp41 trimer.


  • Predicting Post-Treatment Control Before It Happens

    Dr. Mohamed Abdel-MohsenThere is a pressing need for identification of blood tests that could help predict the likelihood of HIV remission after stopping antiretroviral therapy (ART) in the setting of HIV cure trials.


  • Mimicking CD4: A Bait and Switch Approach to Immunotherapy

    This month we focus on another form of immunotherapy, also with the potential to facilitate eradication of HIV reservoirs as part of an HIV cure strategy.


  • CAR Cells, Revved Up

    hen sought to determine if those cells could be enhanced with improvements on three fronts: 1) an increased ability to differentiate into mature, HIV-fighting cells; 2) enhanced resistance to infection and destruction by HIV; and 3) with improved anti-HIV capabilities.   


  • Reversing HIV Latency and Decreasing the Viral Reservoir: Clues from Cancer

    Research Question HIV persists in a dormant state primarily in T cells expressing surface proteins known as immune checkpoint (IC) molecules. These surface molecules normally act as brakes that prevent an overly reactive immune response. In the setting of HIV, ICs might hamper efforts to cure by keeping the virus in immune cells in a […]


  • Risks and Potential Benefits of Participating in Cure Research

    Perceptions of cure trial participants concerning personal and community risks and benefits are relevant to such studies and have received little attention. 


  • Immunotherapy Targeting HIV Reservoirs

    Research Question CAR T cell therapy, which uses T cells that have been engineered to target specific proteins, has revolutionized the treatment of some blood cancers. Yet success in HIV has lagged and several challenges remain. For example, how can we ensure that the CAR T cells go to the areas where they are needed? […]


  • Prospects for an HIV/AIDS Cure: Opinions of People with HIV and Their Healthcare Providers

    The authors concluded that educational strategies tailored specifically to each group are required to increase understanding of HIV cure research and the role of ATI.


  • Mining the Blood for Markers of the Reservoir

    The authors concluded that “the development of these tools may represent simple biomarkers for the rapid evaluation of changes in viral replication outside of the blood and changes in the reservoir size.”


  • HIV Reservoirs in the Blood and Gut Respond Differently to Virus Activators

    The authors conclude that “it will be critical to evaluate the efficacy of LRAs in both blood and tissues” in order to develop more effective therapeutics in HIV cure strategies.


  • The Past, Present, and Future of HIV Reservoir Cells

    Research Question The HIV reservoir consists of HIV-infected cells that are difficult to characterize because to date they have been indistinguishable from uninfected cells. Once the HIV inside infected cells is activated, many of the surface and interior characteristics change. While activated reservoir cells are easier to identify and isolate from blood samples, these fundamental […]


  • A Conversation with the San Francisco Patient

    Loreen Willenberg is an elite controller (EC) – one of the rare individuals who control HIV infection without antiretroviral therapy. ECs were recently described in new and unprecedented detail in the prestigious journal Nature. Loreen was among the ECs the researchers studied. For all intents and purposes, she may be considered “cured” of HIV. Loreen […]


1 | 2 | 3